Advocacy intelligence hub — real-time data for patient organizations
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Zynyz
(retifanlimab-dlwr)Orphan drugIncyte Corporation
Programmed Death Receptor-1 Blocking Antibody [EPC]
12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytoki...
Lisa Lancaster, M.D.
Endeavor Biomedicines
Stacey Cohen
Fred Hutch/University of Washington Cancer Consortium
Andre TC Chen, MD, PhD
Instituto do Cancer do Estado de Sao Paulo
Rohit Joshi, MD, DDS
Cancer Research South Australia
📍 PHOENIX, AZ
Scot C. Remick, MD, MD
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
📍 SCARBOROUGH, ME
Scott Irwin, MD, PhD
Cedars-Sinai Medical Center